MacroGenics (MGNX) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
8 Apr, 2026Voting matters and shareholder proposals
Election of three Class I directors to serve until the 2029 Annual Meeting or until successors are appointed.
Ratification of Ernst & Young LLP as the independent registered public accounting firm for fiscal year ending December 31, 2026.
Advisory vote to approve executive compensation as disclosed in the proxy materials.
Approval of an amendment to the 2023 Equity Incentive Plan.
Board of directors and corporate governance
Board recommends a vote in favor of all proposals presented at the annual meeting.
Three nominees for Class I director positions are Scott Koenig, Federica O'Brien, and Eric Risser.
Audit committee and external auditor matters
Audit Committee selected Ernst & Young LLP as the independent auditor for the next fiscal year.
Shareholders are asked to ratify this selection at the annual meeting.
Latest events from MacroGenics
- Board recommends voting for all proposals, including director elections and equity plan amendment.MGNX
Proxy filing8 Apr 2026 - Key ADC and checkpoint programs advance toward major 2026 milestones, backed by strong partnerships.MGNX
Barclays 28th Annual Global Healthcare Conference12 Mar 2026 - Sharpened R&D focus, robust cash, and advancing ADCs position for value-driving milestones.MGNX
The Citizens Life Sciences Conference 202611 Mar 2026 - Focused execution and pipeline progress set up major clinical milestones for mid-2026.MGNX
Leerink Global Healthcare Conference 202610 Mar 2026 - 2025 net loss widened to $74.6M, but cash runway extends into late 2027 amid pipeline progress.MGNX
Q4 202510 Mar 2026 - Innovative antibody platforms drive a diverse oncology pipeline with key 2026 milestones ahead.MGNX
Corporate presentation9 Mar 2026 - Pipeline advances in ADCs and strategic partnerships drive innovation and financial strength.MGNX
TD Cowen 46th Annual Health Care Conference3 Mar 2026 - Promising clinical progress and strong funding position drive oncology pipeline toward key 2024–2025 milestones.MGNX
Goldman Sachs 45th Annual Global Healthcare Conference3 Feb 2026 - Strong efficacy and improved safety seen for vobra duo in mCRPC; mature data due in 2025.MGNX
Study Update20 Jan 2026